On Tuesday, Shares of XOMA Corp (NASDAQ:XOMA), lost -3.45% to $0.927.
XOMA Corporation, offered a corporate update and stated its financial results for the quarter ended June 30, 2015.
“We knew our endocrine portfolio would be important to XOMA regardless of gevokizumab’s role. Recently, it takes center stage,” stated John Varian, Chief Executive Officer of XOMA. “Our XMet platform, which is focused on the insulin receptor, has been quite active for several years. We brought XOMA 358, an antibody that reduces the binding of insulin to its receptor, from the bench to the clinic and are ready to enter Phase 2 development in two rare hyperinsulinemic hypoglycemia conditions. We have a second Phase 2-stage asset, in addition to several other preclinical- and research-stage programs that provide a critical mass in our endocrine portfolio. In addition, we conducted some very interesting work that has resulted in XOMA 089, an anti-TGF beta monoclonal antibody, which has potential as an important immuno-oncology therapy. We actively are working to out-license those pipeline assets that do not align with our areas of focus as sources of non-dilutive funding to advance those that do.”
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçets disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
Shares of J M Smucker Co (NYSE:SJM), declined -1.45% to $108.91, during its last trading session.
The J. M. Smucker Company, will conduct its first quarter fiscal 2016 earnings conference call and webcast on Thursday, August 27, 2015, at 8:30 a.m. Eastern Time. Earnings will be released the morning of the call.
The J. M. Smucker Company manufactures and markets branded food products worldwide. It operates through four segments: U.S. Retail Coffee; U.S. Retail Consumer Foods; U.S. Retail Pet Foods; and International, Foodservice, and Natural Foods.
Finally, Telefonica S.A. (ADR) (NYSE:TEF), ended its last trade with -0.03% loss, and closed at $15.40.
Telefónica, presented its results corresponding to the first semester of 2015 and reports a net profit of 3,693 million euros, double the amount reached in the same period of 2014 (+105.4%). Additionally, the Company has raised revenue growth guidance for the full year to >9.5 % (vs. >7% formerly).
Telefónica consolidates its new growth cycle quarter after quarter. Up until June, and in stated terms, merged revenue grew +12.5% to 23,419 million euros, OIBDA raised +7.2% to 7,320 million euros, and earnings per share (0.75 euros per share) doubled contrast to the same period of 2014. At the end of June, Telefónica Group’s customer base raised +13% yoy to 329,4 million accesses.
Second quarter numbers of the year confirm the new growth cycle started in the previous quarter and show an acceleration in the organic evolution of revenue and OIBDA growing +4.4% and +3.3% respectively between April and June (+12.4% and +6.8% in stated terms). This growth is based on a generalized improvement of the competitive positioning driven by a high value customer base (fibre, pay TV, LTE, “smartphones”) and supported as well by the investments made on modernizing and transforming the networks. In fact, Telefónica Group CapEx during the first half of the year grew +66.4% to 5,094 million Euros.
Telefónica, S.A. provides fixed and mobile communication services primarily in Europe and Latin America. The company offers mobile voice, value added, mobile data and Internet, wholesale, corporate, roaming, fixed wireless, and trunking and paging services. It offers fixed telecommunication services, counting PSTN lines; ISDN accesses; public telephone; local, domestic, and international long distance and fixed-to-mobile communications; corporate communications; supplementary and business oriented value-added; video telephony; intelligent network; and telephony information services, in addition to leases and sells handset equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
